Although it entered phase I clinical trials in this regard, BPC-157 is not certified by the US Food and Drug Administration (FDA) for medical use
- when there is risk of torsades de pointes, for example in patients with prolonged QT, concomitant administration of other medications that produce torsades de pointes (amiodarone, quinidine, bepridil, IV erythromycin, halofrantine, pentamidine, sparfloxacin, sultopride, vincamine, betrilio, disopyramide, sotalol, etc)
Mechanism of Action Mimics GHRH to trigger natural pulsatile GH release Promotes IGF1 production through GHliver axis Supports fat metabolism, tissue repair, and lean mass retention Best when combined with GHRPs or ghrelin mimetics like MK677 Enhances sleep quality, especially when dosed before bed CJC1295 increases plasma growth hormone and IGF1 levels in a dose-dependent, sustained-release manner while preserving physiologic GH rhythm. Teichman et al., The Journal of Clinical Endocrinology & Metabolism Applications Recovery from intense training or injury GH optimization without suppressing natural production Fat loss and improved body composition Sleep improvement and circadian rhythm regulation Works synergistically with: BPC157 tissue healing and inflammation control TB500 muscular and joint recovery MK677 long-term GH support GHRP2 amplifies GH pulse strength Delivery and Dosing CJC1295 without DAC : Inject subcutaneously 12x per day , 100200 mcg CJC1295 with DAC : Inject once per week , 12 mg Best administered fasted in the morning , post-workout , or before bed TB500 Overview and How It Works TB500 is the synthetic version of Thymosin Beta4 , a naturally occurring peptide involved in tissue repair, inflammation reduction, and cell migration
The most vulnerable include: Methionine Cysteine Tryptophan Tyrosine Histidine Asparagine These amino acids are more likely to undergo: Oxidation Deamidation Structural rearrangement As their numbers increase, overall peptide stability usually decreases
doi:10.1371/journal.pone.0040365 Philippova M, Joshi MB, Pfaff D, Kyriakakis E, Maslova K, Erne P, Resink TJ (2012) T-cadherin attenuates insulin-dependent signalling, eNOS activation, and angiogenesis in vascular endothelial cells
